New lung cancer combo aims to shrink tumors before surgery

NCT ID NCT06623656

Recruiting now Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining the immunotherapy drug cemiplimab with either chemotherapy or targeted radiation (SBRT) before surgery can eliminate or shrink non-small cell lung cancer more effectively. About 112 people with stage IB to III (N2) lung cancer will receive one of the two combinations before their operation, then continue cemiplimab for a year after. The main goal is to see how many patients have no cancer left in their removed tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cemiplimab (Libtayo) with either platinum-based chemotherapy or stereotactic body radiation therapy (SBRT)
What this could lead to: If successful, this could point toward a more effective pre-surgery treatment for non-small cell lung cancer, potentially improving survival rates.
What could go wrong: This is a phase 2 trial with only 112 participants, so results are preliminary. The combination treatments may cause significant side effects, and not all patients will respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchial neoplasm bronchogenic carcinoma lung neoplasm neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Weill Cornell Medicine
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.